Bristol-Myers Squibb Settles FCPA Charges of Bribing Health Professionals in China

Posted 11/10/15

Another global medical company has settled charges of bribing Chinese health care providers (HCPs) to increase sales. Pharmaceutical giant Bristol-Myers Squibb (BMS) agreed Oct. 5, 2015, to pay more …

This item is available in full to subscribers.

Please log in to continue

Log in